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Background: Extended hepatectomy may be required to provide the
best chance for cure of hepatobiliary malignancies. However, the
procedure may be associated with significant morbidity and mortality.
Methods: We analyzed the outcome of 127 consecutive patients
who underwent extended hepatectomy (resection of  5 liver
segments) for hepatobiliary malignancies.
Results: The patients underwent extended hepatectomy for colorec-
tal metastases (n  86; 67.7%), hepatocellular carcinoma (n 12;
9.4%), cholangiocarcinoma (n 14; 11.0%), and other malignant
diseases (n 15; 11.5%). Thirty-two left and ninety-five right
extended hepatectomies were performed. Eight patients also under-
went caudate lobe resection, and 40 patients underwent a synchro-
nous intraabdominal procedure. Twenty patients underwent radio-
frequency ablation, and 31 underwent preoperative portal vein
embolization. The median blood loss was 300 mL for right hepa-
tectomy and 600 mL for left hepatectomy (P  0.02). Thirty-six
patients (28.3%) received a blood transfusion. The overall compli-
cation rate was 30.7% (n 39), and the operative mortality rate was
0.8% (n  1). Significant liver insufficiency (total bilirubin level 
10 mg/dL or international normalized ratio  2) occurred in 6
patients (4.7%). Multivariate analysis showed that a synchronous
intraabdominal procedure was the only factor associated with an
increased risk of morbidity (hazard ratio HR, 4.9; P  0.02). The
median survival was 41.9 months. The overall 5-year survival rate
was 25.5%.
Conclusions: Extended hepatectomy can be performed with a near-
zero operative mortality rate and is associated with long-term sur-
vival in a subset of patients with malignant hepatobiliary disease.
Combining extended hepatectomy with another intraabdominal pro-
cedure increases the risk of postoperative morbidity.
(Ann Surg 2004;239: 722–732)
Without treatment, the prognosis of primary and second-ary hepatic malignancies is dismal. Because primary
treatment with medical therapy does not yield durable results,
hepatic resection is considered to be the optimal treatment
modality with a cure rate between 20% to 35%.1,2 Unfortu-
nately, many patients with malignant hepatic tumors are not
candidates for resection due to the extent of their underlying
liver disease or the burden of tumor present in their liver.
Extended hepatectomy (resection of  5 liver seg-
ments) may be the only means available to achieve complete
resection and provide a chance for cure in some patients with
multiple or large tumors. Although recent advances in patient
selection and surgical technique have resulted in low mortal-
ity after liver resection,3,4 the mortality rate for extended
hepatectomy is  5% and the morbidity rate is  50%.5–9 A
recent study reported an association between perioperative
complications and the number of segments resected.5
The objective of this study was to review our experi-
ence with extended hepatic resection to identify the variables
associated with morbidity, mortality, and survival. A more
detailed understanding of the factors associated with periop-
erative risks could optimize the selection of patients most
likely to benefit from extended hepatic resection versus al-
ternative surgical and/or medical treatment.
PATIENTS AND METHODS
Between October 1993 and April 2003 a series of 127
consecutive patients underwent extended hepatic resection
(resection of  5 liver segments) performed by 2 surgeons
(JNV and SAC). All patients with histologically confirmed
primary or metastatic hepatic malignancies with no clinical,
radiographic, or intraoperative evidence of unresectable ex-
trahepatic disease were eligible. In all cases, extended hepatic
resection was performed with curative intent.
Preoperative Assessment
All patients were evaluated preoperatively with a base-
line history and physical examination; serum laboratory tests
including liver function tests and hepatitis B and C virus
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serology were performed as appropriate. In the first 5 years of
the study, a computed tomography (CT) with arterial portog-
raphy and more recently a helical CT with rapid injection of
intravenous contrast (3 to 5 mL/s) and 5-mm cuts through the
liver were performed; if needed, further imaging was ob-
tained as previously described.10 Patients presenting with
biliary obstruction underwent preoperative endoscopic and/or
percutaneous biliary drainage to provide effective clearance
of jaundice and/or cholangitis.
In the absence of definite compensatory hypertrophy as
a result of tumor growth, patients who were candidates for an
extended right hepatectomy underwent 3-dimensional recon-
struction of the future liver remnant (FLR) (Couinaud seg-
ments II  III  I) as previously described.11,12 The ratio of
the measured FLR volume:total estimated liver volume was
determined using a formula that is derived from the associ-
ation between total liver volume and body surface area
(BSA): Total Liver Volume (cm3)  794.41  1267.28 
BSA (m2).13,14 On the basis of previous volumetric studies,
we used  20% of the total estimated liver volume as the
minimal safe FLR in most patients.12 Those patients with an
anticipated small FLR underwent embolization of the right
and segment IV portal vein branches using an ipsilateral
percutaneous approach to initiate hypertrophy of the FLR
before resection.13,15 After portal vein embolization (PVE),
repeat CT scans were obtained at 3 to 4 weeks to assess for
the extent of compensatory hepatic hypertrophy. Surgical
decision-making was then appropriately based on post-PVE
CT volumetric analysis.
Surgical Techniques
In most cases, an initial incision was made 2 cm below
the right costal margin extending from the midline to the right
flank. If there was no evidence of extrahepatic disease, the
incision was extended to a bilateral subcostal incision or up
along the midline (hockey stick incision). Upon entering the
abdomen, a more thorough exploration was performed to rule
out contraindications to resection (eg, extensive or unresect-
able extrahepatic disease and/or gross lymphadenopathy). An
intraoperative ultrasound (IOUS) was systematically per-
formed to confirm the preoperative imaging and to review the
intrahepatic portal and hepatic vein anatomy.
We have previously described the technique of ex-
tended right and left hepatectomy in detail.16 In most patients
extrahepatic division of the vascular inflow vessels was
performed (portal vein and hepatic artery). Control of the
right or left hepatic veins and of the middle hepatic vein, as
appropriate, was also performed in most cases. The hepatic
parenchyma was divided using the ultrasonic dissector and
cautery (ValleyLab, Boulder, CO), as well as more recently
the Tissuelink (TissueLink Medical Inc., Dover, NH). Major
portal triad and hepatic veins were ligated or suture ligated
with nonabsorbable sutures. During parenchymal dissection a
Pringle maneuver was performed to reduce blood loss.17 The
Pringle maneuver was applied by intermittently occluding the
hepatic artery and portal vein for periods up to 15 minutes
separated by 5 minutes of restored flow.
For those patients undergoing simultaneous radiofre-
quency ablation (RFA), the RF 2000 or 3000 generator
system (Boston Scientific Corp., Natick, MA) and a LeVeen
monopolar needle electrode (4.0-cm maximum array diame-
ter) was used. The RF 2000 system consists of a generator
that supplies up to 100 W of power, while the RF 3000
provides up to 200 W of power. The LeVeen needle electrode
is a 15-gauge insulated cannula that contains 10 to 12 indi-
vidual hook-shaped electrode arms that are deployed in situ.
For tumors 	 2.5 cm in diameter, the multiple array was
deployed into the center of the tumor. For larger lesions, the
array was first deployed at the most posterior interface (ul-
trasonographically) between tumor and normal liver paren-
chyma; it was subsequently withdrawn and redeployed at
1.5-cm intervals in the tumor. The electrode was optimally
positioned to achieve complete destruction of tumor and at
least a 1-cm zone of normal liver parenchyma when possible.
Two anesthesiologists (JFA and DLK) dedicated to the
liver resection team assisted in most cases. In all patients, the
primary goal was to minimize infusions and/or transfusions
until the parenchymal transection was completed. Transient
hypotension associated with hepatic mobilization (eg, in case
of large hepatic tumors) was treated with vasopressor support
(usually phenylephrine) rather than infusion or transfusion. In
most instances, infusions or transfusions were delayed until
the end of the parenchymal transection to maintain a low
central venous pressure with a minimal acceptable urine
output of 0.5 mL/kg per hour. After completion of parenchy-
mal transection and hemostasis, the patients received infusion
of crystalloids and/or albumin to render them euvolemic.
Postoperative Care
After hepatic resection, a predetermined clinical care
pathway that included the timing of patient mobilization, diet
progression, and the ordering of laboratory studies guided
postoperative care. Patients were seen in follow-up within 1
month of discharge, every 3 to 4 months up to 3 years after
treatment, and every 6 months thereafter. CT scan of the
abdomen, a chest radiograph, and serum laboratory tests were
obtained at the time of each follow-up visit.
For purposes of this study, the following were collected
for all patients: patient age and sex; tumor histology, number,
location, and size; type of surgical resection; operative de-
tails; estimated blood loss (EBL); the total number of units of
blood or blood products transfused within the same hospital
stay; disease status; follow-up date; death date; complication
data. Distribution of complication rates and survival time
were analyzed in relation to the different variables collected.
Univariate tests (log-rank) were used to test for differences in
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these distributions by any single factor. Those factors that
appeared to have significant impact on survival or time to
progression were entered into a Cox proportional hazards
model to test for significant effects while adjusting for mul-
tiple factors simultaneously. Perioperative mortality was de-
fined as mortality within 30 days of surgery or within the
same hospital stay. P values were considered as significant
for P 	 0.05. Continuous variables were reported as median
and range unless stated otherwise.
RESULTS
A total of 127 extended hepatic resections were per-
formed. There were 71 men (55.9%) and 56 women (44.1%)
with a median age of 58 years (range, 28 to 81 years).
Extended hepatic resection was used to treat metastatic colo-
rectal cancer in the majority of cases: 86 patients (67.7%).
Cholangiocarcinoma was the second most common diagnosis
(n  15; 11.8%), and hepatocellular carcinoma (HCC) was
the third (n  13; 10.2%), whereas other lesions were less
common (Table 1). The median tumor size was 5.5 cm
(range, 0.7 to 26.0 cm), and the median number of tumors
was 2 (range, 1 to 12). Thirty-one patients (all with right
hepatectomies) underwent preoperative PVE, with the major-
ity of the PVEs occurring after 1999 (n  24; 77.4%) (Fig.
1A). There was an 8.8% increase in the median percent FLR
after PVE (25.8%) compared with before PVE (17%). Sev-
enteen patients (13.4%) presenting with obstructive jaundice
underwent preoperative endoscopic and/or percutaneous bil-
iary drainage before resection.
Thirty-two extended left hepatic resections (25.2%) and
95 extended right hepatic resections (74.8%) were performed.
The number of extended resections significantly increased
over time (P  0.04) (Fig. 1B). In addition to an extended
hepatic resection, 8 patients (6.3%) underwent simultaneous
caudate lobe resection and 40 (31.5%) underwent a synchro-
nous intraabdominal procedure (common bile duct resection,
n  16; resection/thrombectomy of the vena cava or portal
vein with or without reconstruction, n  6; small and large
bowel resection, n  6; major  50% diaphragmatic resec-
tion, n 5; right adrenalectomy, n 4; pancreatectomy, n
2; and Nissen fundoplication, n  1). There was a significant
increase in the number of synchronous procedures performed
during the last 5 years of the study (1999 to 2003) (n  29;
72.5%) compared with the first (1993 to 1998) (n 11; 27.5%)
(P  0.001) (Fig. 1A). RFA was also carried out in 20 patients
(15.7%) at the same time as the extended hepatic resection.
Twelve (60%) of these patients underwent an extended left
hepatic resection, and 8 (40%) had an extended right hepatec-
tomy. In general, there was no difference in the median number
of tumors (n  2; range, 1 to 12) in patients who underwent
RFA compared with those who did not. However, subset anal-
ysis of only patients with colorectal metastases revealed that
patients who underwent synchronous extended resection and
RFA were more likely to have  5 tumors (P  0.004). Of the
20 RFA procedures, 19 (95%) were performed in the year 2000
or later (P  0.008) (Fig. 1A).
The median operative time was 385 minutes (range,
180 to 977 minutes). The median central venous pressure
before parenchymal transection was 6 (range, 1 to 14). A
Pringle maneuver was used in 116 (91.3%) patients, with a
median clamp time of 27 minutes (range, 4 to 94 minutes).
Only 5 patients had a clamp time longer than 60 minutes; 1
of these 5 patients experienced postoperative hepatic dys-
function (bilirubin  3 mg/dL). During the course of the
operation, the hepatic vein was isolated in 23 (63.9%) of 36
extended left resections and 77 (84.6%) of 91 extended right
resections. The median operative blood loss was 600 mL
(range, 100 to 3500 mL) for an extended left hepatectomy
TABLE 1. Demographics and Perioperative Results
Median (range) n (%)
Demographics
Median age (yr) 58 (28–81)
Gender
Female 56 (44.1)
Male 71 (55.9)
Histology of hepatic disease
Colorectal metastasis 86 (67.7)
Cholangiocarcinoma 15 (11.8)
Hepatocellular carcinoma 13 (10.2)
Neuroendocrine metastasis 5 (3.9)
Gallbladder carcinoma 4 (3.1)
Sarcoma metastasis 2 (1.6)
Breast metastasis 1 (0.8)
Cloacogenic carcinoma metastasis 1 (0.8)
Perioperative results
Operating time (min) 385 (180–977)
Pringle maneuver (min) 27 (4–94)
Central venous pressure (mmHg) 6 (1–14)
Estimated blood loss (mL)
Right extended resection 300 (100–1500)
Left extended resection 600 (100–3500)
Patients requiring transfusions 36 (28.3)
Hepatic vein control
Overall 100 (78.7)
Extended left hepatectomy 23 (18.1)
Extended right hepatectomy 77 (60.6)
Associated procedure
Preoperative biliary drainage 17 (13.4)
Preoperative portal vein embolization 31 (24.4)
Radiofrequency ablation 20 (15.7)
Additional intraabdominal procedure 40 (31.5)
Hospital stay (days) 8 (4–39)
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and 300 mL (range, 100 to 1500 mL) for an extended right
hepatectomy (P  0.02). Of note, the median blood loss was
the same in those patients who underwent a synchronous
intraabdominal procedure compared with those who did not
(median, 550 mL in both groups; P  0.54). There was no
statistical trend in blood loss with regard to the year in which
surgery was performed (P  0.82). Of the 127 patients, 36
(28.3%) received a blood transfusion. Patients who under-
went an extended left hepatectomy were more likely to
require a transfusion (P  0.03).
The median hospital stay after extended hepatic resec-
tion was 8 days (range, 4 to 39 days) with no difference
between extended left and right hepatectomy patients. The
overall postoperative complication rate was 30.7% (n  39).
Twenty-four complications (18.9%) were liver-related,
whereas 15 (11.8%) were not (Table 2). Of the 12 patients
with hepatic insufficiency, only 6 (4.7%) had severe hepatic
insufficiency (total bilirubin  10 mg/dL and/or international
normalized ratio (INR)  2 more than 2 days after resec-
tion),18,19 whereas the other 6 experienced clinically signifi-
cant ascites and/or encephalopathy. Univariate analysis re-
vealed that male gender (P  0.02), age  65 years (P 
0.04), and performance of a synchronous intraabdominal
procedure (P  0.04) were all associated with a higher
complication rate. Other factors, such as tumor size, number
of tumors resected, date of surgery, preoperative PVE, ex-
tended right versus left hepatectomy, EBL, RFA, and type of
hepatic malignancy, did not significantly affect the postoper-
ative complication rate (all P  0.05). On multivariate
analysis, the only factor associated with an increased risk of
morbidity was the history of a synchronous intraabdominal
procedure performed at the time of the extended hepatic
resection (hazard ratio (HR)  4.9; P  0.02). Male gender
and age failed to maintain significance on multivariate anal-
ysis.
Only 1 postoperative death occurred (n 1; 0.8%). The
patient was a 49-year-old, otherwise healthy woman with
HCC. Due to extensive disease, she had received prolonged
preoperative chemotherapy consisting of 5-fluorouracil, -in-
terferon, and capecitabine followed by hepatic artery chemo-
embolization. After responding to preoperative therapy, she
underwent an extended right hepatectomy combined with
RFA of segment III. Her operative course was uncompli-
cated; blood loss was 900 mL with an in-flow occlusion time
of only 16 minutes. Her initial postoperative course was
notable for transient hepatic dysfunction (total bilirubin level,
5.8 mg/dL). However, the patient shortly thereafter devel-
FIGURE 1. (A) RFA, PVE, and an associated intraabdominal
procedure were all significantly more common within the last
5 years of the study period. (B) Thirty-two extended left
hepatic resections (25.2%) and 95 extended right hepatic
resections (74.8%) were performed. The number of extended
resections significantly increased over time (P  0.04).
TABLE 2. Postoperative Complications
n (%)
Hepatic complications (n  24; 18.9%)
Perihepatic fluid collection (sterile) 3 (2.4)
Perihepatic abscess 4 (3.1)
Bile leak 5 (3.9)
Hepatic insufficiency* 12 (9.4)
Non-hepatic complications (n  15; 11.8%)
Atrial fibrillation 1 (0.8)
Postoperative bleeding† 1 (0.8)
Sepsis 1 (0.8)
Wound dehiscence 1 (0.8)
Prolonged postoperative ileus 2 (1.5)
Gastrointestinal anastomotic leak 3 (2.4)
Pneumonia 3 (2.4)
Superficial wound infection 3 (2.4)
Total complication rate 30.7%
*Bilirubin  10 mg/dL unrelated to biliary obstruction or leak and/or
INR  2 more than 2 days after resection and/or clinically significant
ascites/hepatic encephalopathy.
†Hemorrhage from the operative site.
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oped pneumonia with subsequent worsening hepatic insuffi-
ciency. Over the ensuing weeks, her total bilirubin rose to
25.1 mg/dL and she developed hepatorenal syndrome, which
led to her demise on postoperative day 39.
At a median follow-up of 18.4 months, the median and
5-year overall survival were 41.9 months and 25.5%, respec-
tively (Fig. 2). Univariate analysis revealed that age, margin
status, and tumor size were significant factors affecting over-
all survival. Younger patients (	 65-year-old) had a median
survival of 71.9 months compared with 31.0 months for
patients  65 years (P  0.01). Likewise, patients with a
positive resection margin (n  21; 16.5%) had a median
survival of only 17.6 months compared with 55.5 months for
those with a negative margin (P  0.02). Whereas patients
with smaller tumors (5 cm) had a median survival of 59.9
months, patients with larger tumors (5 cm) had a median
survival of 36.9 months (P  0.01) (Fig. 3A). Although not
statistically significant, patients who had RFA at the time of
extended hepatic resection showed a trend towards worse
survival. Patients undergoing extended hepatic resection plus
RFA had a median survival of 14.8 months compared with
44.5 months for all other patients (P  0.15) (Fig. 3B). Other
factors, such as gender, history of PVE, extended right versus
left hepatic resection, a simultaneous associated procedure,
EBL, and tumor number, did not significantly affect survival
on univariate analysis (all P  0.05) (Fig. 4). On univariate
analysis, the overall survival of patients with colorectal me-
tastasis (55.6 months) did not differ significantly from pa-
tients with noncolorectal disease (42.0 months) (P  0.35).
On multivariate analysis, both the size of the tumor and
a history of RFA performed at the time of the extended
hepatic resection significantly affected survival. Patients who
had a tumor size  5 cm had a higher likelihood of death than
those who underwent resection for a lesion 5 cm (HR 3.54;
confidence interval CI  1.44 to 8.72; P  0.01). Similarly,
the need to perform RFA for additional disease in the remaining
unresected segment of liver was associated with a poor outcome
(HR  3.34; CI  1.15 to 9.72; P  0.03).
DISCUSSION
The first elective liver resection is credited to Langen-
buch, who in 1888 performed a bisegmentectomy II  III.20FIGURE 2. Overall and median survival for the entire cohort.
FIGURE 3. (A) Patients with a tumor size  5.0 cm had a
significantly worse median survival (36.9 months) compared
with those patients with tumors  5 cm (59.9 months) (P 
0.01). (B) Similarly, although not statistically significant on
univariate analysis, those patients who had RFA at the time of
extended hepatic resection had a worse median survival (14.8
months) compared with patients who underwent only ex-
tended hepatic resection (44.5 months) (P  0.15). On mul-
tivariate analysis, a history of concomitant RFA and extended
hepatic resection was a significant risk for worse overall survival
(HR  3.34; P  0.03).
Vauthey et al Annals of Surgery • Volume 239, Number 5, May 2004
© 2004 Lippincott Williams & Wilkins726
It was not until 1952, however, that Lortat-Jacob reported the
first anatomic extended right hepatectomy. The procedure
included a thoracoabdominal incision, extrahepatic control of
both the inflow and outflow vessels of the right liver, as well
as resection in the plane between segment IV and bisegment
II  III.21 Since then, the techniques of extended right
hepatectomy (Couinaud segments IV - VIII) and extended
left hepatectomy (Couinaud segments II–V and VIII) have
been described in detail.16,22 In fewer than 2 decades, hepatic
resection has evolved from a procedure with an associated
mortality rate of up to 20% to less than 5%.23,24 Extended
hepatectomy, however, remains a complex procedure with
recent reports of mortality  5% and morbidity  50%, even
at specialized centers.5,6 In the current study, we report a near
zero (0.8%) mortality rate and a 30.7% morbidity rate for 127
consecutive extended hepatectomies. This improvement is
multifactorial and undoubtedly related to better patient selec-
tion, improved anesthetic monitoring, greater understanding
of hepatic anatomy, advances in surgical technique, and
improved perioperative critical care.
One improvement has come in the area of patient
selection for extended hepatectomy. In the past, patients with
cholangitis and obstructive jaundice underwent extended he-
patic resection. Several studies, however, have shown that
cholangitis and hyperbilirubinemia are both strongly associ-
ated with increased in-hospital mortality.6,25 In one study, the
presence of preoperative cholangitis or an elevated bilirubin
(6 mg/dL) was associated with a mortality rate of  40%
after extended hepatectomy.6 In another study of 218 patients
undergoing major hepatic resection for biliary tract carci-
noma, Kanai et al found that preoperative cholangitis resulted
in a greater than 2-fold increase in hospital mortality.25
Nimura et al26,27 and Makuuchi et al28 have recommended
routine preoperative biliary drainage before resection to
achieve a bilirubin level less than 3 mg/dL. In the series
reported here, all patients presenting with biliary tract ob-
struction underwent preoperative biliary drainage to achieve
clearance of cholangitis and/or jaundice. In general, it appears
that hyperbilirubinemia adversely affects the ability of the
liver to regenerate, causing an inhibition in such critical
transcription factors as hepatocyte nuclear factor-6 (HNF-6)
and HNF-4, both of which are important for hepatocyte
function, repair, and regeneration.29,30
Traditionally, measures such as indocyanine green
(ICG) retention rate, galactose elimination, and aminopyrine
clearance have been used to evaluate hepatic metabolic func-
tion and hepatic functional reserve. Most experience with
ICG comes from Japan, with this test not being widely used
in the West, though retention rates of 15 minutes after
intravenous injection of ICG (0.5 mg/kg) correlate with
outcome in some series.31,32 We believe, however, that these
tests are impractical for surgical planning before extended
hepatectomy, as they provide an overall measurement of
function and do not differentiate between the liver to be
resected and the anticipated liver remnant. Our group has
therefore focused on the evaluation of the FLR volume as the
most important factor indicative of an increased risk for
complications.12,13
In general,  20% of the total liver volume appears to
be the minimum safe volume that can be left after extended
resection in patients with normal underlying liver. CT can
now provide an accurate and reproducible method for preop-
erative liver volume calculation using three-dimensional CT
volumetry.12,14 In 48 patients without chronic liver disease
undergoing extended hepatectomy with and without preoper-
ative portal vein embolization, the postoperative complica-
tion rate was significantly increased in patients with FLR
volume  20% of the total estimated liver volume.12 Shirabe
et al has also demonstrated correlation between liver volume
and outcome in patients with chronic liver disease using a
FIGURE 4. Neither a history of preoperative PVE (A) nor the
type of extended resection performed (right versus left) (B)
had an effect on overall survival.
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standardized method of calculation based on body surface
area.33 In this study, all deaths from liver failure occurred in
patients with FLR 	 300 mL/m2. Small liver remnant size
has been associated with increases in portal pressure and
flow, endothelial and Kupffer cell injury, and the release of
pro-inflammatory cytokines.34 Surrogate measures of the
overall postoperative course, such as hospital stay and inten-
sive care unit stay, also appear to be increased as the FLR
decreases.13 Thus, unlike other investigators who have pre-
viously suggested that the number of segments resected
dictates perioperative morbidity and mortality,5 it is now
becoming clear that the true critical factor is the size of the
FLR.35 Our data support this contention, as one of the reasons
for the low morbidity and mortality rates seen in the current
series may be our systematic use of preoperative volumetry in
the selection of patients for extended hepatectomy.
To avoid operating on patients with small FLR, patients
with FLR  20% of the total liver volume underwent pre-
operative embolization to induce hypertrophy of the con-
tralateral liver. PVE is safe with less than a 5% complication
rate, causes little periportal reaction, and generates durable
portal vein occlusion, especially when used in combination
with coils.15 PVE has been shown to increase both the size
and function of the FLR.36,37 In the current series, 31 patients
underwent preoperative PVE, all of whom had an increase in
FLR before extended resection. PVE was exclusively per-
formed in patients undergoing an extended right hepatic
resection, as PVE is rarely necessary before extended left
hepatectomy because the right posterior sector constitutes

30% of the total liver volume.38,39
Although clearly important, an adequate liver remnant
is not an absolute safeguard against postoperative complica-
tions. Regardless of the FLR volume, massive intraoperative
bleeding can result in postoperative hepatic compromise.
Multiple studies have shown a relationship between intraop-
erative blood loss and poor outcomes after major hepatic
resection.6,40,41 Massive blood transfusions can add to the
risk of coagulopathy as well as exert immunosuppressive
effects. Melendez et al6 reported that blood loss  3 L was a
key operative variable associated with increased in-hospital
mortality. Similarly, Matsumata el al41 found an increase in
abdominal septic complications in patients experiencing
blood loss  3 L. Didolkar et al40 also reported that blood
loss  5 L resulted in increased postoperative mortality. In
our series, only 1 patient experienced a blood loss  3 L,
whereas the median blood loss was considerably lower: 600
mL (range, 100 to 3500 mL) for a left extended hepatectomy
and 300 mL (range, 100 to 1500 mL) for an extended right
hepatectomy (P  0.01). Of the 127 resections reported here,
only 28.3% of patients received a transfusion.
A number of factors contributed to the low blood loss
seen in the current series. One important factor is the relation
between intraoperative blood loss and the pressure within the
inferior vena cava (IVC). In the current series, we minimized
infusions and transfusions until the end of the parenchymal
dissection. In a prospective study examining blood loss and
IVC pressure, Johnson et al42 showed a direct linear correla-
tion between mean caval pressure and blood loss. Surgical
technique, however, is likely the most important factor in
minimizing blood loss. In extended right hepatectomy, a
complete dissection of the anterolateral vena cava and control
of the right hepatic vein may reduce blood loss. This maneu-
ver not only provides vascular control, but it also allows for
an anterior mobilization of the liver to be resected, which
facilitates visualization and intraparenchymal dissection. He-
patic vein control was performed in the majority of cases
(78.7%) in the current series, and this may have also contrib-
uted to the low intraoperative blood loss. Other studies have
corroborated this, with one study showing that use of hepatic
vein control considerably reduced blood loss.43 Another tech-
nique proven to reduce blood loss and consequently improve
surgical outcome is the Pringle maneuver.44 In the current
study, a Pringle maneuver was used in 116 patients (91.3%),
with a median clamp time of 27 minutes (range, 4 to 94
minutes).
The complication rate for extended hepatic resection in
this study was 30.7%, which is comparable to the 21% to
45% morbidity rates reported overall for hepatic resections.5,7
Most of the complications were minor or intermediate, in-
cluding perihepatic collections that were amenable to percu-
taneous drainage. Serious complications were less common,
including 6 patients (4.7%) who had significant hepatic in-
sufficiency as defined as a total bilirubin  10 mg/dL or an
INR  2.19,32 On univariate analysis, male gender (P 
0.02), age  65 years (P  0.04), and performance of a
synchronous intraabdominal procedure (P  0.04) were all
associated with a higher complication rate.
Previous studies have reported conflicting results about
the importance of gender with regards to perioperative mor-
bidity.45,46 In the current analysis, gender did not withstand
competing risk in the multivariate analysis. Similarly, there
have been divergent reports on the association between ad-
vanced age and morbidity after hepatic resection.6,47,48 In the
current study, on multivariate analysis, age also failed to
remain a significant factor in determining morbidity. One
factor that did maintain significance on both univariate and
multivariate analysis was the history of a synchronous intra-
abdominal procedure performed at the time of the extended
hepatic resection (HR  4.9; P  0.02). Others have also
shown that concomitant procedures, such as biliary or vas-
cular resections, are associated with higher morbidity.3,5 Of
note, there was a significant increase in the number of
synchronous procedures performed during the last 5 years of
the study (P  0.001), which corresponded to an increase in
associated morbidity. Caution, therefore, needs to be taken
when combining extended hepatectomy with another intraab-
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dominal procedure, and staged procedures deserve consider-
ation in selected patients when possible.
At a median follow-up of 18.4 months, the median
overall survival was 41.9 months. Two factors seemed to
affect overall survival. On multivariate survival analysis, both
the size of the tumor and a history of RFA performed at the
time of the extended hepatic resection significantly affected
survival. Patients who had a tumor size  5 cm had a higher
likelihood of death than those who underwent resection for a
lesion  5 cm (HR  3.5; P  0.01). Previous studies have
also shown a correlation between tumor size and survival.
Similarly, the need to perform RFA for additional disease in
the remaining unresected segment of liver was associated
with a poor long-term outcome (HR  3.3; P  0.03). In the
current study, tumor size and the need to RFA residual
disease in the contralateral lobe after extended hepatectomy
may have acted as surrogate markers for overall tumor
burden.
Some have argued that extended hepatic resection for
colorectal metastases is unwarranted because the combination
of high perioperative mortality and inferior survival did not
translate into a long-term benefit.49 In the current study, we
showed that extended hepatectomy can be accomplished
safely and is associated with long-term survival. At times,
preoperative PVE will be needed to ensure an adequate FLR.
When combining resection with an additional intraabdominal
procedure, the peri-operative risk is increased and the ap-
proach should be individualized.
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Discussions
DR. ALAN W. HEMMING (Gainesville, Florida): When
first reading the manuscript I thought the title “Is Extended
Hepatectomy for Hepatobiliary Malignancy Justified?” was
clearly rhetorical, since any liver surgeon has no doubt that
the answer is yes.
When asked to discuss this paper, I informally asked
my non-liver surgery medical and surgical colleagues what
they thought about taking out three-quarters of the liver for
cancer, and it was surprising to find out that the general
feeling was that it was probably all we had to offer but that
the results were not very good.
This paper from Dr. Vauthey is important in that it
demonstrates the excellent results that can be currently ob-
tained with extended hepatic resections by specialized hepa-
tobiliary surgeons. Dr. Vauthey has presented a series of 127
consecutive patients undergoing extended hepatectomy over
a 10-year period with a commendable operative mortality of
less than 1%. These results were achieved by applying tech-
niques that are becoming standards for liver surgery, includ-
ing the ability to control inflow and venous outflow to the
liver, low CVP during parenchymal transection, dedicated
liver anesthesiologists, and preoperative portal vein emboli-
zation to optimize the projected liver remnant post-resection.
Dr. Vauthey, I have several questions regarding the paper.
In the manuscript you made a point of relating compli-
cations from liver resection not to the amount of liver re-
sected but to the amount of liver left behind. You put the
emphasis on calculating FLR and using this information to
select patients for extended resection and seemed to be
against using functional tests such as indocyanine green
clearance. Indocyanine green clearance is generally used to
assess the amount of hepatocellular reserve in cirrhotic pa-
tients rather than in patients with normal liver function. Your
series was largely if not completely performed in noncirrhotic
patients with colorectal liver metastases and presumably
normal liver function. Do you think that FLR assessment
alone is adequate information to assess the ability of a
cirrhotic liver to tolerate an extended resection? In our cir-
rhotics we would currently perform calculations of both FLR
and ICG retention at 15 minutes, using ICGR-15 cut-off of
15% with extended resection.
Second question. The results of extended hepatectomy
with RFA to lesions in the remnant liver appear to be
relatively worse than without RFA. Have your recurrences
been primarily hepatic or extrahepatic? Our experience has
been there is a fair amount of recurrence within the liver and
we have begun placing hepatic artery infusion pumps for
adjuvant therapy in these patients. What is your current
approach to HAI pumps in these patients, or what other
therapy are you giving to these patients at high risk for
recurrence?
Third question. Your operative mortality of less than
1% is commendable. And as surgeons I suppose that we all
should be aiming at a zero percent operative mortality. This
is perhaps more of a philosophical question. But is zero
percent operative mortality truly what we are aiming at, or
would that suggest that we are overly selecting our patients
and at the same time not performing resections in patients that
may benefit? I have no real answer to that. I would be
interested in your opinion.
DR. JOHN S. BOLTON (New Orleans, Louisiana): The
presentation by Dr. Vauthey is notable for an admirably low
operative mortality rate, less than 1%, and low rate of
postoperative hepatic insufficiency after extended hepatic
resection. Given the median overall survival of almost 5 years
for patients with metastatic colorectal cancer and 42 months
overall for all patients, the authors confirm that extended
hepatic resection is an endeavor worth pursuing.
The data suggest that preoperative measurement of
future liver remnant and the application of selective portal
vein embolization to patients with a predicted low FLR
enhances safety. But the data presented doesn’t prove this,
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since many other measures, including fastidious biliary drain-
age and preoperative treatment of cholangitis, reduction in
the numbers of patients with massive blood loss, a dedicated
anesthesiology team, and perhaps unidentified patient selec-
tion factors might be responsible for some or all of the
mortality reduction.
Also, the paper doesn’t provide good confidence inter-
vals given the small sample size for selected subpopulations.
One such subpopulation is patients with hilar cholan-
giocarcinoma, especially if hepatic artery or portal vein
reconstruction is required. They had 15 patients in their series
with hilar cholangiocarcinoma; a sample size this small
creates wide confidence intervals for the operative mortality
endpoint. A second subgroup, patients who required concom-
itant bowel resection or major vascular reconstruction of any
type, consists of only 12 patients.
For a third subgroup, patients over the age of 70 or 75,
my teaching and training always was beware of liver regen-
eration in this elderly population. But what is their mortality
from an extended hepatic resection? We probably don’t have
the sample size to give us good confidence intervals in this
paper.
I have several questions for Dr. Vauthey. Among the 13
patients with hepatocellular carcinoma, how many had un-
derlying chronic liver disease and how many of these patients
underwent portal vein embolization?
Second, for hilar cholangiocarcinoma were multiple
biliary drainage catheters placed in most patients? That is, did
you not only drain the future liver remnant but also drain the
site to be resected? And how about segment 1 drainage? That
always seems to be sort of a well of sepsis that is difficult to
drain preoperatively.
And my third question, did you encounter NASH or
non-alcoholic steatohepatitis in your patient groups? How do
you recognize it? And does it preclude extended hepatic
resection?
DR. LAYTON F. RIKKERS (Madison, Wisconsin): In cal-
culating the residual volume of the liver, is the liver occupied
by tumor included in the calculation?
DR. MARTIN J. HESLIN (Birmingham, Alabama): I rise to
congratulate Dr. Vauthey and his colleagues. This is a large
and impressive series.
Many patients undergoing extensive resections have
large tumors or tumors that are placed in poor locations. We
find that a lot of these patients undergo preoperative chemo-
therapy, and we have noticed anecdotally that some patients
with more extended resections and preoperative chemother-
apy have either a higher risk of hepatic failure or an increased
risk of complications subsequently.
I may have missed it in your talk, but did you mention
how many people received preoperative chemotherapy and
have you noted if there is a relationship between liver failure
and any one particular chemotherapeutic agent?
DR. JEAN-NICOLAS VAUTHEY (Houston, Texas): First, in
answer to Dr. Hemming, we would agree that ICG is a tool
for estimating hepatic reserve. It has been demonstrated to be
useful in Japan especially for resection of small tumors in
patients with advanced cirrhosis. However, in the West we
are talking very often of patients with large tumors, and
perhaps compensatory hypertrophy, and measuring the he-
patic function globally with ICG may not be meaningful in
these patients. You really need to focus on the part that is
going to remain after resection, and you cannot determine
accurately how much functional parenchyma you will be
removing by doing ICG. So it is a general estimate that is
good in cirrhosis and in the resection of small tumors. The
Japanese have used, in fact, the future remnant in addition to
ICG in patients with cirrhosis who need major hepatectomy.
Regarding radiofrequency ablation, Dr. Abdalla will
talk about the intrahepatic recurrence rate and our current
results. We have used intra-arterial chemotherapy as part of a
phase II adjuvant chemotherapy protocol after resection and
ablation but have been disappointed by the results (Ann Surg
Oncol 2003; 10:348–354). We have essentially discontinued
the use of intra-arterial chemotherapy as adjuvant therapy in
patients who undergo complete resection of colorectal me-
tastasis given the recent advances in effective systemic che-
motherapy such as oxaliplatin or irinotecan based regimens.
Are we selecting the patients? Maybe. I would like to
note that the last patient presented here, who is a 10-year
survivor, was a patient for whom I sent the x-ray to Dr.
Blumgart in New York and Dr. Blumgart asked me to send
him the patient for resection. Do we have patients with
chronic liver disease in this series? Yes, we have patients
with steatosis. But we don’t have patients with fibrosis or
cirrhosis.
How do we drain our patients before surgery? We
initially focus on draining the future liver remnant in patients
with hilar cholangiocarcinoma. In some patients, we have had
difficulty in doing portal vein embolization when there was
dilation on the side to be embolized. So for this reason, and
because we use portal vein embolization and an ipsilateral
approach for portal vein embolization we have been draining
both sides recently. But we would certainly accept a drain, a
single endoscopic drain, well placed going to the left side in
a patient, who is going to undergo an extended right hepa-
tectomy in the absence of jaundice if the future liver remnant
is adequate in size.
Dr. Rikkers is asking about our method of measurement
of the future liver remnant. We have developed a method of
measurement that is similar to that used in transplantation and
is essentially based on the future liver remnant. And for this
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liver remnant measurement, the numerator is the absolute
volume obtained by CT volumetric reconstruction, which for
an extended right hepatectomy is segment II and III volume
directly measured from CT, and as a denominator we use the
total liver volume based on a formula that is based on body
surface area which we have developed (Liver Transpl 2002;
8:233–240). So our measurements are all standardized for the
size of the patients. Small patients need small liver remnants.
Large patients need large liver remnants.
Dr. Heslin asked about preoperative chemotherapy and
the risk of steatosis and damage from chemotherapy. We
recently published a paper specifically looking at steatosis in
patients who received irinotecan based systemic chemother-
apy (J Gastrointest Surg 2003; 7:1082–1088). We did not find
a significant increase in steatosis in these patients. We have
graded the steatosis in this study and I think if you use 3 or
4 cycles of systemic chemotherapy before resection this is a
safe approach.
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